1-5 of 5
Patricia Harris
Close
Sort by
Journal Articles

A Phase 1 Study of ACTR087 in Combination with Rituximab, in Subjects with Relapsed or Refractory CD20-Positive B-Cell Lymphoma

Javier Munoz, MD, Samantha Jaglowski, MDMPH, Matthew S. McKinney, MD, Iris Isufi, MD, Patrick J. Stiff, MD, Jessica Sachs, MD, Ann Ranger, PhD, Patricia Harris, MPH, Francis Payumo, BSc, MSc, Luke P. Akard, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 244.
https://doi.org/10.1182/blood-2019-123810
Published: 2019
Journal Articles

Preliminary Clinical Results from a Phase 1 Study of ACTR707 in Combination with Rituximab in Subjects with Relapsed or Refractory CD20 + non-Hodgkin Lymphoma

Ian W. Flinn, MD PhD, Jason R. Westin, MD, Jonathon B. Cohen, MDMS, Luke P. Akard, MD, Samantha Jaglowski, MDMPH, Jessica Sachs, MD, Ann Ranger, PhD, Patricia Harris, MPH, Francis Payumo, BSc, MSc, Veronika Bachanova, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1587.
https://doi.org/10.1182/blood-2019-125995
Published: 2019
Journal Articles

Preliminary Clinical Results of a Phase 1 Study Evaluating the Safety and Anti-Tumor Activity of ACTR707 in Combination with Rituximab in Subjects with Relapsed or Refractory CD20+ B-Cell Lymphoma

Ian W. Flinn, MD PhD, Jonathon B. Cohen, MD MS, Luke P. Akard, MD, Samantha Jaglowski, MD MPH, Michael Vasconcelles, MD, Ann Ranger, PhD, Patricia Harris, MPH, Francis Payumo, BSc, MSc, Greg Motz, PhD, Veronika Bachanova, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2966.
https://doi.org/10.1182/blood-2018-99-111622
Published: 2018
Journal Articles

Preliminary Safety and Efficacy Of IPI-145, a Potent Inhibitor Of Phosphoinositide-3-Kinase-δ,γ, In Patients With Chronic Lymphocytic Leukemia

Ian Flinn, MD, PhD, Manish Patel, MD, Brad S. Kahl, MD, Steven M. Horwitz, MD, Francine M. Foss, MD, Yasuhiro Oki, MD, Pierluigi Porcu, MD, Jennifer Sweeney, BS, Kerstin Allen, MA, Kerrie Faia, MS, Patricia Harris, MPH, Joi Dunbar, PharmD, Howard M. Stern, M.D., Ph.D., Patrick Kelly, MD, Susan O'Brien, MD
Journal: Blood
Blood (2013) 122 (21): 677.
https://doi.org/10.1182/blood.V122.21.677.677
Published: 2013
Journal Articles

Safety and Management of Toxicities in the BELA Trial of Bosutinib Versus Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia

Carlo Gambacorti-Passerini, MD, Jorge E Cortes, Patricia Harris, Christine Powell, Athena Countouriotis, Hagop M Kantarjian
Journal: Blood
Blood (2011) 118 (21): 1685.
https://doi.org/10.1182/blood.V118.21.1685.1685
Published: 2011